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abstract
Background: Solitary fibrous tumor is the second primary malignancy of the pleura and can reach up to 39 cm in dia-
meter; however, to be referred to as “giant” it must occupy at least 40% of the affected hemithorax. Although this tumor 
usually shows a benign behavior, malignancy criteria have been described. The aim of the study was to assess the initial 
evaluation, diagnostic procedures, surgical management, treatment outcome, and prognosis.
methods: We performed a descriptive, observational, longitudinal, and retrospective study from 2002 to 2006 on pa-
tients who underwent surgery with a diagnosis of giant solitary fibrous tumor of the pleura. 
results: Six patients were included; 83.3% were females. Mean age was 48 years. All patients were symptomatic, 
mainly dyspnea, cough and chest pain; 66.7% were left-sided. Preoperative angiography and embolization were per-
formed in 83.3% cases with successful surgical resection. The predominant blood supply was derived from the internal 
mammalian artery. Intraoperative complication rate was 17%. A vascular pedicle was found in 66.7%. The largest lesion 
was 40 cm in diameter and weighed 4500 g. Only one case showed high mitotic activity. Mean follow-up to date is 14 
months.
Conclusions: Symptomatology found was consistent with previous reports but in higher percentages. Accurate diagno-
sis is critical because surgical resection involves a potential cure; however, long-term follow-up is mandatory. Preopera-
tive embolization is recommended due to tumor size.
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introduction
Most pleural neoplasms have a metastatic origin. Primary 
pleural tumor can be categorized as diffuse (diffuse ma-
lignant mesothelioma) or localized (previously referred to 
as localized mesothelioma and now referred to as “fibrous 
solitary tumor” or “localized fibrous tumor of the pleura”); 
the latter has a controversial histogenesis.1-3
Localized fibrous tumor of the pleura was first described 
by Wagner in 1870; however, it was not until 1931 when 
Klemperer and Rabin described it pathologically as a sepa-
rate entity.3-5 This entity has received diverse names such 
as localized mesothelioma, benign fibrous mesothelioma, 
fibrous solitary mesothelioma, localized benign fibroma, 
submesothelial fibroma, pleural fibroma and subserous fi-
broma.6-8 
Approximately 800 cases have been reported in the in-
ternational literature, and this entity has frequently been 
confused with pleural mesothelioma.3,9 This disease rep-
resents <5% of pleural neoplasms with a prevalence of 
~2.8/100,000 tumors.4,10-12 Some authors report that it 
constitutes 8% of benign thoracic neoplasms and 10% of 
pleural tumors,6 being the second most important pleural 
primary tumor after malignant mesothelioma10 and repre-
senting <1% of the total surgical activity of the thorax.4
This disease affects both males and females without racial 
specificity and is more frequent during the sixth and sev-
enth decades (although it may affect any age group).1-3,7,13,14 
Some authors have reported a higher affection in males15,16 
as well as a family relationship between mother and daugh-
ter.3 Other authors have reported an associated  involvement 
from chromosomes 8 and 12,17-20 particularly trisomy 8 and 
trisomy 21, finding a relationship between tumor size and 
genetic abnormalities. This suggests that these chromosom-
al defects can promote tumor growth.21
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Fibrous tumors of the pleura are solitary, although ex-
tremely rare cases with synchronous lesions have been 
reported22 as well as intrapulmonary lesions17 (7.5% of 
cases23,24). The latter are referred to as inverted fibromas1 
and are associated with these two characteristics.6 The tu-
mor is generally encapsulated, measuring on average 5-6 
cm in diameter with reports including 1-39 cm in diameter1 
and with a weight up to 5200 g.25 The tumor may also be 
lobulated.26 
“Giant” tumors receive this name when they occupy at 
least 40% of the affected hemithorax.27 They have a fibrous 
grayish-white surface1,13,26 alternating with soft areas, necro-
sis and hemorrhage. Sections reveal nodules composed of 
densely agglutinated fibrous tissue and may contain cystic 
structures from several millimeters to 5 cm in diameter with 
clear viscous liquid in up to 10-15% of cases.1,13 A short 
peduncle has been described in 38-50%,2,13,24 and is about 
<1 cm in length.13 In up to 66% of cases, this peduncle at-
taches to the visceral pleura13,24,28 and can be vascularized 
in larger tumors, associated with increased vascularity.1,8 
The presence of a peduncle usually indicates a benign tu-
mor, independent of histological characteristics7 that show 
formation from fusiform homogeneous cells in a densely 
hyalinized fibrous stroma and rarely calcified (0.9%).13 
Atypical cell formations and mitosis are infrequent.2,29 
These tumors originate due to mesenchymatous growth 
produced from visceral or parietal pleura.4,9 Tumors from 
visceral origin are more frequent,2 representing >80% of 
cases.11 Immunohistochemical tests have confirmed that 
these tumors do not have a mesothelial origin4,7,28 but are 
more likely to originate from primitive mesenchymatous 
submesothelial cells.2,3,28,30 These lesions show a low prev-
alence on the right hemithorax.31 Tumors developing in 
atypical places are malignant (thoracic wall parietal pleura, 
diaphragm, mediastinum, lung fissures, intraparenchyma-
tous).1,13 Because solitary fibrous tumors can originate in 
peritoneum, pericardium, mediastinum, meninges, lung, 
heart, thyroid, parotid glands, kidney, adrenal glands, blad-
der, ocular orbit, oral cavity, epiglottis, nose and paranasal 
sinuses, it has been suggested that these entities may origi-
nate from a common stem cell present in several organs and 
tissues and possibly have a myofibroblastic origin.5-8,11,32-34
Patients and methods
We carried out a descriptive, observational, longitudinal and 
retrospective study between January 1, 2002 and December 
31, 2006, which included all patients intervened and diag-
nosed with giant fibrous solitary tumor of the pleura at the 
National Institute of Respiratory Diseases “Dr. Ismael Co-
sio Villegas” in Mexico City. The purpose of our study was 
to report the experience obtained in management of this 
rare pathology as well as to carry out an extended review of 
diagnostic and therapeutic approaches based on a selective 
literature review. Descriptive statistical analysis was car-
ried out using basic statistics.
results
Of seven cases found, we excluded one because of the fi-
nal diagnosis as monophasic synovial sarcoma. Of six cases 
included in our study, 83.3% (n = 5) were females with an 
average age of 48 years (range: 30-72 years) without preva-
lence in any age group. Exposure to asbestos or tobacco was 
not documented in any case. Only systemic arterial hyper-
tension was observed in one case (16.7%) as a comorbidity. 
All patients were symptomatic, presenting dyspnea, cough 
and thoracic pain as the most frequent symptoms (Figure 
1).
Posteroanterior chest x-ray was carried out in all cases, 
estimating tumor volume at an average 70% of affected 
hemithorax (range: 50-95%), observing contralateral me-
diastinal deviation in all cases dependent on tumor size. 
Computed tomography (CT) of the chest was carried out in 
all patients without clearly identifying vascular peduncle or 
invasion to other structures. Magnetic resonance imaging 
(MRI) studies were not carried out. 
Fine needle aspiration biopsy (FNAB) was carried out in 
only one case; however, this was not diagnostically useful. 
In three cases (50%) true-cut biopsy was carried out, result-
ing in a diagnosis in 66.7% of cases (n = 2). 
In 66.7% (n = 4) of cases, the tumor was located on the 
left side. In four cases the tumor also had a parietal pleura 
origin showing a prevalence on the mediastinal pleura in 
three cases, whereas the other two cases were diaphragmat-
ic with only 33.3% originating from visceral pleura. 
Preoperative angiography and embolization were carried 
out in 83.3% (n = 5) of cases, all of them female, identifying 
arterial contribution with a prevalence of internal mammary 
artery (100%, n = 5) as well as bronchial arteries (60%, n = 
3) and phrenic arteries (40%, n = 2).
Embolization was carried out with polyvinyl alcohol mi-
crospheres in all cases. Only one case reported paresis of 
lower right limb from medullary ischemia, which receded 
2 weeks later without further consequence, resulting in a 
20% morbidity rate attributable to procedure. All embolized 
cases underwent surgical resection at an average of 7 days 
after procedure (range: 2-18 days). The range reaches 18 
days because of medullary ischemia presented in one case. 
Complete tumor resection was carried out in all em-
bolized cases (n = 5) through posterolateral thoracotomy 
approach. The other case was partially resected (demon-
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figure 1. Symptoms reported in studied cases.
strated through microscopy). In case of complete tumor 
resection, an additional pulmonary parenchyma V-shaped 
resection was carried out. Average intraoperative bleeding 
was 1908.3 ml (range: 650-3300 ml). The patient who had 
the highest amount of bleeding (3300 ml) required packing 
of the thoracic cavity that was resolved in 24 h, resulting 
in an intraoperative complication rate of 16.7%. There was 
zero mortality. No case required adjuvant therapy. 
All tumors were solitary with an average size of 29.3 cm 
(range: 24-40 cm) at their largest diameter with an aver-
age weight of 2567 g (range: 1700-4500 g). In 66.7% (n = 
4) of cases, a vascular peduncle was identified, three were 
dependent on the parietal pleura and the other on the vis-
ceral pleura with an average diameter of 1.75 cm (range: 
1-3 cm). All lesions were encapsulated and none presented 
evidence of invasion to other structures. High mitotic ac-
tivity was identified in only one case (16.7%) (>4 mitosis 
per 10 high-power fields) that corresponded to a malignant 
tumor. Table 1 presents macro- and microscopic findings 
and Figure 2 illustrates preoperative tests and postoperative 
x-rays of case 3. 
Immunohistochemical tests were negative in all cases for 
cytokeratins, bcl-2, SMA, EMA, S-100 protein, desmin and 
calretinin and positive in all cases for CD34 and for vimen-
tin in 83.3% of cases.
Average follow up was 14 months (range: 2-33 months). 
One relapse was documented in the nonembolized patient 
who also experienced incomplete tumor resection. Re-
lapse occurred 4 months after follow-up, demonstrating 
a 16.7% relapse rate. The patient was reintervened due to 
a tumor in the apex of the lung and fourth costal arch. 
Histopathological tests reported high-grade pleomorphic 
sarcoma compatible with giant-cell malignant fibrous his-
tiocytoma, resulting in a malignant transformation rate of 
16.7%. 
discussion
Solitary fibrous tumors of the pleura may be benign or ma-
lignant when they diffusely infiltrate lung parenchyma29 or 
adjacent structures.1 The benign variant is an encapsulated 
lobulated tumor without a microscopically defined pattern 
and may appear as a sarcomatoid mesothelioma with in-
serted fascicles from ovoid or fusiform cells with poorly 
defined borders and scarce cytoplasm, without atypia, and 
with cells inversely proportional to collagen.7,13 Malignant 
variant (~10-33% of cases) is characterized by high cel-
lularity, accented pleomorphism (expressed as increased 
nuclear grade) and high mitotic activity (>4 mitosis per 10 
high-power fields7,13),1,4,9,11,35-37 and usually presents necrosis 
or hemorrhage.1-2 These five histological criteria plus the 
possibility of pleural effusion, atypical location and adja-
cent structure invasion have been established as malignant 
indicators by England et al.13 (Table 2) and accepted by the 
American Registry of Pathology;38-40 however, only mitotic 
index has shown a statistically significant association with 
poor biological behavior,6 as we observed in our study. 
Only one of England’s criterion is required, even focused, 
to regard the tumor as malignant.24 We did not consider the 
presence of necrosis and hemorrhage to classify malignancy 
because of the time elapsed between preoperative emboliza-
tion and surgical procedure (average: 7 days; range: 2-18 
days) because the literature mentions that this period should 
be reduced to hours. Even though most cases are reported as 
benign, malignant behavior has been reported in long-term 
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follow-up,7,37 which is not always referred to histological 
criteria of malignancy41 (Table 2). The rate of benign vs. 
malignant tumors has been reported as 7:115,40 with an inci-
dence of invasive behavior in 13-23% of cases.32
Contrary to mesotheliomas, solitary fibrous tumors of 
the pleura report negative immunohistochemical results for 
cytokeratins3,9 (although malignant variations occasionally 
report positive results41 and express through submesothelial 
cells under certain circumstances31), positive to vimentin 
and CD343,4,24 (Table 3), positive in 29-50% of cases to 
Kit (CD117),35,42 and have no relationship with exposure 
to asbestos2,4,35 or tobacco.2 However, they can present an 
unpredictable biological behavior, sometimes with local re-
currence and metastases even with negative CD34. These 
negative results may be useful for biological prognosis.6,14 
It has been reported that a strong p53 expression with nega-
tive CD34 and high Ki67 index (proliferative index) are 
associated with poor biological behavior (Table 2).36,43,44 
The Ki67 antigen is associated with cell proliferation 
and is part of DNA replicase complex. Its presence indi-
cates proliferative activity in diverse tumors and in contrast 
with proliferative cellular nuclear antigen (PCNA), which 
intervenes also in DNA repair. It is virtually restricted as 
a proliferation antigen, which provides a better indicator 
table 1. Macro- and microscopic findings in analyzed cases
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
Age 30 46 50 54 38 72
Gender F F F F F M
Embolization Yes Yes Yes Yes Yes No
Full resection Yes Yes Yes Yes Yes No
Size (cm) 27 x 20 x 7 40 x 30 x 15 24 x 20 x 9 24 x 22 x 22 32 x 26 x 18 29 x 17 x 9
Weight (g) 2500 2000 1700 2700 4500 2000
Invasive – – – – – –
Encapsulated + + + + + +
Necrosis + + – – + –
Hemorrhage + + – – + –
Cystic contents – – – Mucous – –
Histological pattern Mixed Hyaline 
degeneration
Fibrous 
hyaline
Mixed Mixed Mixed
Calcification – – – + – –
Atypia Mild – Mild Mild Mild –
Cellular density Intense Intens Moderate Moderate Moderate Moderate
Mitosis 0 0 1-2 1-4 1-4 1-5
Free borders Yes Yes Yes Yes Yes No
Classification Benign Benign Benign Benign Benign Malignant
M, male; F, female; +, Present; –, Absent.
of growth fraction. MIB1 is a monoclonal antibody de-
veloped against Ki67 antigen.45 Proliferative index (Ki67/
MIB1) indicates the number of dividing (proliferating) 
cells in a tumor and can be used jointly with S-phase frac-
tion to provide a better understanding of the rate of tumor 
growth.21,46 It is expressed as the percentage of stained 
nuclei in a sample47 (0-10% in benign tumors, 20-40% in 
malignant tumors21). There are contradictory reports about 
the expression of estrogen and progesterone receptors and 
their association with malignancy because of the small sam-
ple size; therefore, further investigation is required.41,48 It 
has been suggested that tumor growth may be accentuated 
during the last trimester of pregnancy possibly because of 
increased hormonal activity.49 
From revised series, only England reports positive re-
sults for vimentin in 81% of cases, whereas the others report 
100% positive results (Tables 3 and 4). England’s series in-
cluded 223 patients and we found positive results in 83.3% 
of cases according to England’s findings despite the much 
smaller sample size.
Vimentin, desmin and keratins are cytoskeletal inter-
mediate filaments (proteins). Vimentin is expressed in all 
mesenchymatous cells that cover (like an epithelium) se-
rous membranes and in fibroblasts, fibrocytes and vascular 
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figure 2. (A,B) Posteroanterior and lateral chest x-rays showing 
homogeneous opacity in left hemithorax with well-defined borders 
that occupies about 60% of hemithorax. Phrenic sinuses are blurred 
and contralateral mediastinum deviation. (C) Angiography showing 
tumor irrigation through left internal mammary artery. (D) Control 
x-ray 2 weeks after surgery. 
table 2. Factors associated with prognosis
Good prognosis Poor prognosis
• Peduncle 
• Tumors <10 cm
• Encapsulated 
• Low pleomorphism 
• Low mitotic activity 
• Full resection 
• No pulmonary invasion
• Calcification
• Low cellularity
• Low proliferative index
• No peduncle
• Tumors >10cm
• High cellularity
• Accented pleomorphism
• High mitotic activity
• Necrosis
• Hemorrhage
• Pleural effusion
Atypical location
• Adjacent structures   
  invasion
• High proliferative index
• p53 overexpression
• CD34–
• Extrathoracic 
symptoms (hypertrophic 
osteoarthropathy, 
hypoglycemia, finger 
clubbing)
endothelial cells. Desmin is associated with skeletal and 
smooth muscle differentiation and keratin is a marker for 
epithelial differentiation.50,51 S-100 protein is a marker of 
peripheral nerve tumors.50 CD99 is produced by the MIC2 
gene and intervenes in regulation of cellular proliferation 
and adhesion.50 Calretinin has a high expression in neurons 
and external nervous system in mesothelial cells; therefore, 
it is used as a mesothelioma marker in differential diagnosis 
involving carcinoma.52
CD34 is a transmembrane protein present in human he-
matopoietic progenitor cells and in vascular endothelium. It 
acts as an ubiquitous antigen in a wide range of histogenic 
cellular types without having a specific lineage and is ex-
pressed by myofibroblasts. Therefore, it is not specific for 
these tumor types and should be interpreted in an appropri-
ate histomorphological context in combination with other 
markers.7,14 Because of its myofibroblast origin, smooth 
muscle actin (SMA) staining is generally negative because 
there are four myofibroblast types and one type does not ex-
press actin.7 Kit (CD117) is a transmembrane receptor with 
tyrosine kinase activity produced by proto-oncogene c-kit, 
which regulates development and growth of certain human 
cell types and has been found in pulmonary and pleural 
tumors. It also intervenes in the development of normal tis-
sue including hematopoietic cells.43 The integral membrane 
protein bcl-2 is produced by proto-oncogene BCL-2 located 
on chromosome 18, which is found in endoplasmic reticu-
lum membrane, nuclear membrane and outer mitochondrial 
membrane. Its function is to prevent apoptosis. Overexpres-
sion of this protein suppresses apoptosis in damaged cells, 
contributing to metastases of some tumors.53 Its expression 
in fibrous solitary tumors of the pleura has a relationship 
with the diameter of the tumor: more positive cells equals 
smaller tumor size. This means that bcl-2 inhibits prolifera-
table 3. Immunohistochemical characteristics 
Marker % Reactivity
Vimentin+ 81-100
CD34+ 90-95
CD99+ > 50
bcl-2+ 50
Kit (CD117)+ 29-50
SMA+ 20
Pancytokeratins– 100
EMA–
S-100 protein−
Desmin−
Calretinin−
SMA, smooth muscle actin; EMA, epithelial membrane antigen.
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tive cell activity through the interaction of still unknown 
additional molecules, which indicates that this protein ex-
erts different biological effects according to cell type.36
Differential diagnoses include pleural mesothelioma, 
neurogenic sarcoma, monophasic synovial sarcoma, he-
mangiopericytoma, fibroblastic sarcoma, and malignant 
fibrous histiocytoma (determined by immunohistochemis-
try),6-7,14 as well as bronchogenic carcinoma,54 metastatic 
pulmonary carcinoma,14 and calcifying fibrous pseudotu-
mor of the pleura.55 Even though pulmonary sequestration 
is not included in differential diagnosis, there is frequent 
misdiagnosis involving this pathology.56 In our series, one 
case diagnosed with monophasic synovial sarcoma (through 
section review) was excluded and required reintervention 
from remnant tumor at 6  months and at 10 months of me-
tastasis. 
Of the patients, 30-60% present symptoms1,4,9,10,14,57 (Table 
5), and this rate reaches 54-67% in benign cases and >75% 
in malignant cases.25 Symptoms depend on tumor size and 
include cough, dyspnea from compressive atelectasis, pleu-
ral pain (common if tumor has a parietal pleural origin) and 
lower limb edema from mediastinum compression.2,9,26,29 
Acropachy and hypertrophic osteoarthropathy secondary to 
abnormal production of hyaluronic acid from tumor cells4 
(Pierre-Marie-Bamberger syndrome12) are found in 20-50% 
of cases. This is the most common associated paraneoplastic 
syndrome25 vs. 6% in patients with mesothelioma9 and are 
associated with a malignant phenotype.10,14 Pleural effusion 
is uncommon in benign tumors (2%) but may be present 
in 10-32% of malignant tumors.2,4,9,13,29,54,58 It is sometimes 
related with other paraneoplastic syndromes such as second-
ary reactive hypoglycemia12,34,59 (Doege-Potter syndrome12) 
from hyperproduction of type 2 insulin-like growth factor 
(pro-IGF2) precursor in 4-5% of cases (2% in benign cases 
and 14% in malignant cases60). It is more frequent in females 
and may exceptionally cause hypoglycemic coma12,61,62 
as well as be related to hyponatremia secondary to inad-
equate secretion of antidiuretic hormone. It may develop 
with rheumatoid arthritis. All these symptoms disappear 
after the tumor is removed.2,4,9,12,25,29 Galactorrhea has also 
been reported1,16,25,58 as well as gynecomastia25 with uncer-
tain etiology. This is an incidental finding in the remaining 
patients.2,4,58 Local symptoms are in relation to the large size 
of the tumor, whereas extrathoracic manifestations are not 
necessarily related.33
In our study we observed symptoms in all patients al-
though dyspnea, coughing and chest pain are the most 
frequent. Prevalence of all symptoms and sign was higher 
than documented in larger literature series (Tables 4 and 5), 
possibly because our series focused on giant tumors.
Fibrous solitary tumors of the pleura cannot be dis-
tinguished from other tumors using simple chest x-ray.1 
Contrast CT shows a heterogeneous aspect with a peduncle 
that usually is attached to visceral pleura,1,2,9,26,63 also pre-
senting reinforcement from a large vascularization (areas 
without reinforcement are related with necrosis, hemorrhage 
or degeneration). Lesions >10 cm in diameter associated 
with central necrosis and pleural effusion increase probabil-
ity of malignancy2 (Table 2). Calcified areas may be found 
in up to 26% of cases,25 and in our series these areas were 
found in 16.7% (n = 1) of cases. Multiple pedunculated tu-
mors attached to visceral pleura are rare.9 
MRI may be useful to evaluate fibrous structure of the 
tumor.2,4 Because 79% of lesions extend toward the lower 
thorax and 28% are adjacent to the diaphragm, both CT and 
magnetic resonance are useful to evaluate the relationship 
between tumor and other structures (including mediasti-
num). These imaging methods can help define the extension 
of infiltration of adjacent structures when present.25,57 In this 
case, MRI shows greater sensitivity.63 
Ultrasound is not useful for diagnosis2 but fluorodeoxyg-
lucose positron emission tomography (FDG-PET) has been 
suggested to identify or discard malignancy prior to sur-
gery.25,64-66 
Preoperative angiography helps to evaluate vascular-
ization of the tumor,67-69 observing hypervascularity from 
aorta-derived arterial contribution and, in some cases, from 
internal mammary artery.2 Occasionally the tumor feeds 
from aberrant blood vessels, phrenic artery branches or 
bronchial artery branches.13  Abdominal aorta contribution 
through renal arteries has been recorded56 and early venous 
drainage is typically not observed.2 In our study we found 
vascularization from internal mammary artery with a small 
contribution from branches of bronchial and phrenic arter-
ies. 
Correct diagnosis is vital because despite the typically 
large size of the tumor, the patient has a good prognosis13,24,33,40 
when the tumor is fully resected,40 observing healing in 45% 
of cases.13 However, because there is a potential malignant 
behavior, all patients (with either benign or malignant tu-
mors63) should adhere to a lengthy follow-up program7,10,11,33 
carrying out control CT scan every 6 months during the first 
2 years and a yearly control CT scan afterwards25,37 because 
most relapses (particularly from sessile malignant tumors 
~63%) occur 24 months after resection. Ideally, long-term 
follow-up should be carried out for 15-20 years.25
Giant tumors may generate partial or full atelectasis as 
well as contralateral mediastinum deviation.70 This is rare-
ly regarded as a simple case because it generally refers to 
pleural fibromas.33 Because of their fibrous and hypocellu-
lar characteristics, a transthoracic FNAB offers little value 
for diagnosis; however, when true-cut11,33,60 or core biopsy 
techniques are used, the biopsy increases its diagnostic 
contribution as demonstrated in our series. Moreover, spe-
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cialized histopathological techniques such as electron 
microscopy and immunohistochemical microscopy can in-
crease biopsy specificity.2,68 Preoperative embolization is 
useful, especially when dealing with large masses2,67,69 be-
cause this reduces intraoperative bleeding.56,67 
The treatment of choice is surgical resection1,4,7,9,14,23,33,57,58,60 
of the tumor, its peduncle and site of origin. Other resections 
are occasionally required: pulmonary, costal wall or en-bloc 
diaphragm (particularly when tumor originates in the pari-
etal pleura4), with 5-year survival rates of 97%.9 Surgical 
approaches include thoracotomy, sternotomy and thoracos-
copy and are selected according to tumor location and size.57 
Although most tumors are benign, they should be removed 
with appropriate free surgical margins of 1-2 cm12,21 because 
this is the best guarantee for avoiding relapses. When using 
video-assisted techniques, tumor content effusion should 
be avoided within the thoracic cavity, particularly when 
removing the lesion.4 This is especially useful for treating 
solitary pulmonary nodules, small fibrous tumors12,60 (<5 
cm54) or tumors located within a fissure60 and mainly when 
resection is technically feasible and images are clear.33 This 
approach has been recommended to evaluate any non-diag-
nosed tumor through biopsy to determine the best surgical 
approach and to avoid invasive thoracotomy.15 However, 
risk-benefit of this diagnostic procedure should be evalu-
ated because it involves anesthesia and surgery. Overall 
intraoperative mortality has been estimated at 12% because 
of hemodynamic changes associated with decompression 
of mediastinal structures.67 Postoperative chemo- and ra-
diotherapy have demonstrated no additional benefits4,7,37,60 
even when performing an incomplete resection,33 which has 
been associated with low cell content and low mitotic ac-
tivity of the tumor.67 However, there is recent reference of 
cases where chemo- and radiotherapy have been useful.21,70 
A precise preoperative diagnosis using neoadjuvant therapy 
is difficult even when a biopsy is available.21,38
These types of tumors may relapse or transform into 
a malignancy, usually nonpedunculated, which is larger 
in size and located in unusual sites. For these cases, the 
treatment of choice is a second resection, which provides 
good, long-term patient survival. Incomplete second re-
section or malignant transformation reduces survival to 
24-36 months.9 On the other hand, repeated resections to 
treat relapses increase technical difficulty.40 Relapses have 
been reported with a prevalence of 1.4-23%6,17,30,36,54 dis-
tant metastases with 0-19% and tumor-related mortality of 
0-27%.6,13 Relapse and metastases generally occur 5 years 
after surgery7 although latency periods up to 31 years have 
been reported.13,10,11 Malignant transformation is unusual;17 
however, malignant fibrous histiocytoma transformations 
have been reported.71 Local relapse after full resection is not 
uncommon in malignant tumors but is exceptionally rare in 
benign lesions. This may be a consequence of incomplete 
resection, unidentified tumor during surgery or growth of a 
nonrelated second tumor.38 However a “contact” mechanism 
has been suggested between these.72 De Perrot et al.21 esta-
table 5. Associated symptomatology
Symptom
Okike, 
197862
England, 
198913
Suter, 
199824
de 
Perrot, 
199937
Rena, 
200163
Magdeleina, 
200254
Sung, 
20055
Carretta, 
200641
Kohler, 
200738
Santolaya, 
200728
n 52 223 15 10 21 60 63 18 27 41
Asymptomatic (%) 54 52 53 30 57 48 43 56 37 24
Chronic cough (%) 33 27 33 20 14 32 8 17 26 29
Pleural pain (%) 23 55 27 50 28 48 25 6 26 24
Dyspnea (%) 19 6 13 50 19 13 17 17 11 19
Fever (%) 17 3 - - - - 2 11 - -
Hypertrophic 
pulmonary 
osteo-arthropathy 
with or without 
acropachy  (%)
19 8 13 - 14 13 2 6 7 -
Pleural effusion (%) 6 17 - 19 23 - - 4 17
Weight loss  (%) 6 10 - 10 14 - 3 6 7 -
Hemoptysis  (%) 2 3 7 10 - - - - - -
Pneumonitis (%) 2 - - 10 - - - - 7 -
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blished a classification in 2002 to stratify relapse risk based 
on histological and morphological markers and a manage-
ment algorithm (Figure 3). They proposed a classification 
for these types of tumors: stage 0⎯pedunculated tumor wi-
thout signs of malignancy; stage I⎯sessile (inverted) tumor 
without malignancy signs; stage II⎯pedunculated tumor 
with signs of histological malignancy; stage III⎯sessile 
(inverted) tumor with histological malignancy signs; stage 
IV⎯multiple synchronous metastatic tumors.
In conclusion, giant solitary fibrous tumors of the pleu-
ra deserve special consideration. Because of their size they 
may trigger several symptoms in patients and surgical re-
moval is technically more difficult. It is advisable to carry 
out preoperative embolization in order to reduce intrao-
perative bleeding. Scarcity of literature in regard to these 
large tumors was an obstacle in carrying out an appropriate 
comparison. Most often they are mentioned in series that 
include lesions of different sizes and are case reports. Fur-
ther studies with additional patients are needed as well as a 
longer follow-up period in order to obtain data with higher 
statistical power.
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